Don’t Call it a Comeback: mHealth Never Went Out of Style

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Across the life sciences industry, global not-for-profit partnerships and pharmaceutical manufacturers alike have become increasingly active in the mobile health space.  In 2012, projections indicated that the global smartphone application market would reach up to $718 million. Already, mobile technologies had helped pharmaceutical and device teams facilitate heightened medical awareness and encourage patient adherence.  Continue reading



The Superstars of Digital Healthcare: MM&M Lists ‘Top 40 Healthcare Transformers’

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Innovations abound within the pharmaceutical digital marketing space. As a whole, the industry has worked to increase the availability of healthcare information and better address the needs of healthcare consumers. In its recent “Top 40 Healthcare Transformers” article, Medical Marketing and Media provides a snapshot of some of the leading industry innovators.  Many executives have leveraged online platforms to connect with unique industry stakeholders.  Others have modified the way patients receive healthcare by creating new—or rethinking existing— telemedicine platforms.  In some cases, companies have even begun connecting patients with doctors who are prepared to make house calls.  Continue reading


Big Data Storage and Privacy in the Pharmaceutical Industry

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Within the last few years, Big Data has become one of the most recognizable buzzwords in marketing.  Especially as the healthcare industry moves more towards cultivating a strong digital presence, life sciences industries are looking for ways to use these data.  With access to a plethora of information — from electronic medical records (EMRs) to clinical trial results — firms are seeking out new ways to leverage pharmaceutical Big Data. Continue reading



Making the Most of Digital Marketing Budgets to Produce Valuable Initiatives

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Attaining and wisely spending online marketing budgets is essential for companies operating in the digital space.  How companies secure their digital marketing budgets and choose to spend them varies across surveyed pharmaceutical and device organizations. Some companies have a formal budgeting process in place for attaining digital marketing funding. Others receive budgets on an ad-hoc basis. Regardless of how these organizations receive their funding, allocating their available resources often marks the difference between companies abilities to develop successful, meaningful digital campaigns versus ones that fall flat after only a few months. Continue reading


The EU and Mobile Health: Increasing Patient Adherence and Healthcare Efficiency While Protecting Consumers

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Research Analyst

Mobile health (mHealth) has been touted for its ability to increase mHealth adherence, facilitate remote data analysis and — if all goes according to plan — revolutionize healthcare as we know it.  The US FDA has only recently released a guidance discussing how it will regulate mHealth initiatives while the EU already has a web of legal framework outlining mHealth regulations.  Cutting Edge Information’s recent study on mHealth finds that Top 20 companies rank EMA and in-country regulations each as a 3.9 out of 5 in terms of difficulty to work with.

But don’t worry app developers of Europe – the EU is on it! Continue reading


Target Acquired: Employing Closed-Loop Marketing to Maximize Physician Segmentation Processes and Refine Pharmaceutical Sales Strategies

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

The pharmaceutical commercial environment is currently in flux as both life science organizations and healthcare professionals adjust to recent changes. Pharmaceutical and medical device organizations are still feeling the impact of two major patent cliffs as well as diminished sales force sizes. Physicians, on the other hand, are responding to evolving regulations, including the 2013 implementation of the Physician Payment Sunshine Act. In many cases, medical institutions and doctors are limiting their interactions with pharmaceutical firms. As prescribers doors close, life sciences organizations must evolve their pharmaceutical sales strategies to meet these physician access challenges. Continue reading